Virosome studied by MedImmune

By Dylan Bushell-Embling
Friday, 18 July, 2008

Technology developed by Norwood Abbey's [ASX: NAL] second-tier subsidiary Virosome Biologicals is being evaluated by US company MedImmune.

The companies have signed a six-month exclusive evaluation agreement over Virosome's virosomal vaccine technology. In this time the companies will collaborate on research using the virosome technology with MedImmune vaccine candidates.

MedImmune is a member of the AstraZeneca group.

Scientists search for cystitis pain 'off switch'

By targeting certain pain receptors in the bladder, Australian scientists believe that the...

Australia's first cases of H5 avian influenza confirmed

Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...

AusBiotech partners with Tenmile

Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...

Content from other channels on our network

Daniel Wyner appointed Lumary CEO

Home care safeguards when disasters hit

"Historic legislation" allows authorised nurses to prescribe PBS medicines

You see what others miss

Tapping into the labour mobility market to fill ongoing workforce gaps

Demand increases for skilled sustainability professionals

Pilot program reduces food waste in SEQ

Yarra Valley Water to report net zero operational emissions

Recycling workers' lives at risk from hazardous waste

Biochar used for solar water purification

Energy crisis will have long‍-‍term effects: Australian Industry Group

Myriota launches hybrid 5G satellite and cellular IoT network

Funding program for smaller businesses to access additive manufacturing

Collaboration provides NZ's largest smart water meter upgrade

ARENA backs Sicona battery technology to boost EV performance